Phase II open label data similar to what was presented in the past, do we really have any new news here?
Investors should be cautioned and careful on this issue:
- I predict the phase 3 will not reproduce the seemingly LDL favorable results of phase 2, while it will continue to present the unfavorable side effects of raising HDL--poorly designed and controlled study by a company with no experience in Rx
- The material cannot be commercialized for FDA approved Rx. Sure, they can sign all the contracts they want to produce a batch of trial material but Krill is a volatile substance refined not like fish oil. It cannot be standardized and has tiny levels of EPA/DHA vs. fish oil. It's hard to manufacturer and hard to keep fresh. Their PR on manufacturer is to try and put a smokescreen up to potential investors--the material is not viable as Rx now, and may never get there.
- 2-4g dose of Krill will make you have a horrendous day. It has a noticeable gastrointestinal impact at those levels
- Parent company is pretty bad shape, no US patents holding up and their base nutritional business is all but diminished to a trickle.
PT ACST $.70; PT NEPT $2.25